Details of the Drug Combination

General Information of Drug Combination (ID: DC1JM6P)

Drug Combination Name
Mometasone Azelastine
Indication
Disease Entry Status REF
Seasonal Allergic Rhinitis Phase 3 [1]
Component Drugs Mometasone   DM45OJN Azelastine   DMXTMBJ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Mometasone
Disease Entry ICD 11 Status REF
Allergic asthma CA23.0 Approved [2]
Allergic rhinitis CA08.0 Approved [2]
Exanthem N.A. Approved [2]
Granuloma annulare N.A. Approved [2]
Intrinsic asthma N.A. Approved [2]
Primary cutaneous T-cell lymphoma N.A. Approved [2]
Skin allergy 4A82 Approved [3]
Asthma CA23 Investigative [2]
Sinusitis CA0A.Z Investigative [2]
Mometasone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Agonist [6]
------------------------------------------------------------------------------------
Mometasone Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Indication(s) of Azelastine
Disease Entry ICD 11 Status REF
Allergic conjunctivitis 9A60.02 Approved [4]
Allergic rhinitis CA08.0 Approved [5]
Seasonal allergic rhinitis CA08.01 Approved [5]
Vasomotor/allergic rhinitis CA08 Approved [5]
Azelastine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [8]
------------------------------------------------------------------------------------
Azelastine Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [9]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [9]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [11]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [10]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)

References

1 ClinicalTrials.gov (NCT05311475) Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis
2 Mometasone FDA Label
3 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7121).
5 Azelastine FDA Label
6 Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92.
7 Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
8 Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
9 In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
10 Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
11 Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Jul;27(7):792-7.